Toll-like Receptor Agonists Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 60+ Companies are working to improve the Treatment of Space | InDex Pharmaceuticals, Mologen, Idera Pharmaceuticals, Exicure, Birdie Biopharmaceuticals/ Seven and E

DelveInsight's, "Toll-Like Receptor Agonist Pipeline Insight 2023" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Toll-Like Receptor Agonist pipeline landscape. It covers the Toll-like Receptor Agonists pipeline drug profiles, including Toll-like Receptor Agonists' clinical trials and nonclinical stage products. It also covers the Toll-like Receptor Agonists therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Toll-like Receptor Agonists Pipeline treatment landscape of the report, click here @ Toll-like Receptor Agonists Pipeline Outlook- https://www.delveinsight.com/report-store/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Toll-like Receptor Agonists Pipeline Report
• DelveInsight's Toll-like Receptor Agonists Pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Toll-like Receptor Agonists.
• The leading Toll-like Receptor Agonists Companies include InDex Pharmaceuticals, Mologen, Idera Pharmaceuticals, Exicure, Birdie Biopharmaceuticals/ Seven and Eight Biopharmaceuticals, and Others
• Promising Toll-like Receptor Agonists Pipeline Therapies include Cobitolimod, Tilsotolimod, and others
• In February 2022, Primmune Therapeutics presented interim data related to PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses and Opportunistic Infections (CROI). Oral administration of PRTX007 in this first-in-human study of healthy volunteers exhibited a favorable safety profile, rapid absorption and conversion to TLR7 agonist PRX034, and activation of the innate immune system, without causing inflammation.
• In March, 2021 Quibim, a global medical imaging analysis specialist, has joined Highlight Therapeutics, a clinicalstage company specialising in immuno-oncology, to assess the efficacy of new immunotherapy treatments inadvanced melanoma skin cancer using AI in a Phase II clinical trial in Spain. The alliance will analyze the informationcontained in radiological scans and correlate these findings with biological changes in patients who are treated withpembrolizumab and BO-112, a synthetic double stranded RNA that is administered as intratumoral therapy inadvanced melanoma.
• In December, 2020 Highlight Therapeutics has initiated a phase 2, single arm, open label, adaptive study todetermine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV)pembrolizumab. Patients will be treated with the combination of BO-112 and pembrolizumab. The study will evaluate the antitumoural activity and systemic exposure of repeated intratumoural injections of BO-112 into a tumoural lesion, in combinationwith intravenously administered anti-PD1. BO-112 has intrinsic anti-tumoural effects, but interestingly acts on severalmechanisms involved in resistance to Toll Like Receptor agonists. Intratumoral (IT) administration of BO-112 will be performedonce weekly (QW) for the first 7 weeks and then once every three weeks (Q3W); pembrolizumab Q3W will be administered IV.The trial enrolled 42 participants and is expected to get completed by August 2023.
• Pattern's lead product, P2PAR-100, is an immunotherapeutic that activates innate immune cells to kill cancer cells and safely activates an efficacious innate and adaptive immune response.

For further information, refer to the detailed Toll-like Receptor Agonists Unmet Needs, Toll-like Receptor Agonists Market Drivers, and Toll-like Receptor Agonists Market Barriers, click here for Toll-like Receptor Agonists Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Toll-like Receptor Agonists Overview
Toll-like receptors (TLRs) are a family of pattern recognition receptors and part of the first line of defense against invading microbes. TLR1, -2, -4, -5, -6, and -10 are expressed on the cell surface, whereas TLR3, -7, -8, and -9 are situated on endosomal membranes within the cell [5, 9, 10]. TLR1 and TLR2 can heterodimerize to recognize a variety of bacterial lipid structures and cell wall components, such as triacylated lipoproteins, lipoteichoic acid, and β-glucans.

Request a sample and discover the recent advances in Toll-like Receptor Agonists Ongoing Clinical Trial Analysis and Medications, click here @ Toll-like Receptor Agonists Treatment Landscape- https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Toll-like Receptor Agonists Emerging Drugs Profile
• Cobitolimod: InDex Pharmaceuticals
Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod met the primary endpoint in the Phase IIb study CONDUCT and demonstrated an outstanding combination of efficacy and safety. In March 2021, InDex Pharmaceuticals announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the Phase III study CONCLUDE. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
• Tilsotolimod: Idera Pharmaceuticals
Tilsotolimod is an investigational, synthetic Toll-like receptor 9 agonist. Intratumoral injection of tilsotolimod has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation. Tilsotolimod has received both Fast Track designation and Orphan Drug designation from the FDA and is being evaluated in multiple tumor types and in combination with multiple checkpoint inhibitors. In March 2021, Idera Pharmaceuticals announced that ILLUMINATE-301, the Company's pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR).

Dive deep into rich insights for drugs for Toll-like Receptor Agonists Market Drivers and Toll-like Receptor Agonists Market Barriers, click here @ Toll-like Receptor Agonists Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Toll-like Receptor Agonists Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Toll- Like Receptor Agonist. The companies which have their Toll- Like Receptor Agonist drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

Scope of the Toll-like Receptor Agonists Pipeline Report
• Coverage- Global
• Toll-like Receptor Agonists Companies- InDex Pharmaceuticals, Mologen, Idera Pharmaceuticals, Exicure, Birdie Biopharmaceuticals/ Seven and Eight Biopharmaceuticals, and Others
• Toll-like Receptor Agonists Pipeline Therapies- Cobitolimod, Tilsotolimod, and others.
• Toll-like Receptor Agonists Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Toll-like Receptor Agonists Mergers and acquisitions, Toll-like Receptor Agonists Licensing Activities @ Toll-like Receptor Agonists Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Toll- Like Receptor Agonist: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Cobitolimod: InDex Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Cavrotolimod: Exicure
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. BDB-018: Seven and Eight Biopharmaceuticals
14. Drug profiles in the detailed report…..
15. Preclinical stage products
16. BDB-030: Seven and Eight Biopharmaceuticals
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Toll- Like Receptor Agonist Key Companies
20. Toll- Like Receptor Agonist Key Products
21. Toll- Like Receptor Agonist- Unmet Needs
22. Toll- Like Receptor Agonist- Market Drivers and Barriers
23. Toll- Like Receptor Agonist- Future Perspectives and Conclusion
24. Toll- Like Receptor Agonist Analyst Views
25. Toll- Like Receptor Agonist Key Companies
26. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.